CIBC Asset Management
NTLA icon

CIBC Asset Management’s Intellia Therapeutics NTLA Stock Holding History

CIBC Asset Management’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-3,132
Closed -$228K – 1409
2022
Q1 		$228K Hold
3,132
– – ﹤0.01% 1265
2021
Q4 		$370K Buy
3,132
+396
+14% +$49.6K ﹤0.01% 954
2021
Q3 		$367K Buy
2,736
+520
+23% +$78.7K ﹤0.01% 924
2021
Q2 		$359K Buy
+2,216
New +$173K ﹤0.01% 909

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

CIBC Asset Management's NTLA Position: Q2 2022 in Review

CIBC Asset Management sold out of Intellia Therapeutics (NTLA) in Q2 2022, closing a stake of 3,132 shares — an estimated $228K sold.

CIBC Asset Management first reported a position in NTLA in Q2 2021 and held it in 4 quarters. The position peaked at $370K in Q4 2021. 299 funds tracked by Wall St. Rank hold NTLA as of Q2 2022.

  • CIBC Asset Management reported no remaining Intellia Therapeutics position as of Q2 2022 after selling out during the quarter.
  • CIBC Asset Management sold 3,132 Intellia Therapeutics shares in Q2 2022, an estimated $228K.
  • CIBC Asset Management first reported a position in Intellia Therapeutics in Q2 2021 and held it in 4 quarters.
  • CIBC Asset Management's Intellia Therapeutics position peaked at $370K in Q4 2021.
  • 299 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2022.

Based on CIBC Asset Management's 13F filing for Q2 2022, filed 9 Aug 2022.